Literature DB >> 25883761

How an Occluded Artery Recanalizes during Acute Stroke Thrombolysis.

Vijay K Sharma1, Leonard Ll Yeo2, Hock L Teoh2.   

Abstract

Entities:  

Keywords:  Acute stroke; CT angiography; Middle cerebral artery; Recanalization; Thrombolysis; Transcranial Doppler

Year:  2015        PMID: 25883761      PMCID: PMC4398789          DOI: 10.4250/jcu.2015.23.1.56

Source DB:  PubMed          Journal:  J Cardiovasc Ultrasound        ISSN: 1975-4612


× No keyword cloud information.
A 46-year-old Chinese man presented with left-sided weakness of sudden-onset for 145-minutes. His cardiovascular risk factors included hypertension and hypercholesterolemia. Neurological examination revealed left hemiplegia (Medical Research Council power grade 0/5) with National Institute of Health Stroke Scale (NIHSS) score of 16-points. An urgent non-contrast brain computed tomography (CT) scan was unremarkable while CT angiography revealed acute occlusion of the proximal right middle cerebral artery (MCA) (Fig. 1A). Treatment with intravenous tissue plasminogen activator (IV-tPA) was initiated at 175-minutes from symptom-onset. Continuous transcranial Doppler (TCD) monitoring of right MCA flow was performed using 2-MHz ultrasound transducer (Supplementary movie 1). No flow signals were noted in right MCA at the time of IV-tPA initiation. At 16-minutes, minimal antegrade flow (Fig. 2A) appeared in the right MCA that improved rapidly normal flow spectra within few seconds (Fig. 2B and C).1) Improvement in TCD flow signals was accompanied by rapid neurological recovery (NIHSS score decreased to 3-points at 20-minutes). He continued to improved and recovered considerably by day 2. CT angiography performed on day 2 revealed complete recanalization of the right MCA (Fig. 1B).
Fig. 1

A: Pre-treatment computed tomographic angiography (CTA) of the brain shows a filling defect in the proximal right middle cerebral artery. B: The image shows the CTA performed on day 2, showing complete recanalization.

Fig. 2

Continuous transcranial Doppler monitoring of the right middle cerebral artery (MCA) was performed to evaluate its patency. A: The image shows the minimal grade flow signals in the right MCA at 16 minutes that improved during next few seconds (B), rapidly becoming normal flow signals (C).

IV-tPA is the only approved therapeutic agent for achieving arterial recanalization in acute ischemic stroke. TCD is a noninvasive and bedside technique that can witness arterial recanalization in real-time during intravenous thrombolysis.2) Various randomized and observational studies provide an indication of the biological effect of TCD ultrasound in enhancing the effect of IV-tPA induced thrombolysis without any compromise on its safety regarding symptomatic intracranial hemorrhage.3) Our case demonstrates the rarely witnessed arterial recanalization of right MCA in real-time during intravenous thrombolysis and continuous TCD monitoring.
  3 in total

Review 1.  The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies.

Authors:  Maher Saqqur; Georgios Tsivgoulis; Francois Nicoli; David Skoloudik; Vijay K Sharma; Vincent Larrue; Jürgen Eggers; Fabienne Perren; Paris Charalampidis; Dale Storie; Ashfaq Shuaib; Andrei V Alexandrov
Journal:  J Neuroimaging       Date:  2013-04-22       Impact factor: 2.486

Review 2.  Role of transcranial Doppler ultrasonography in evaluation of patients with cerebrovascular disease.

Authors:  Vijay K Sharma; Georgios Tsivgoulis; Annabelle Y Lao; Andrei V Alexandrov
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

3.  Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator.

Authors:  A M Demchuk; W S Burgin; I Christou; R A Felberg; P A Barber; M D Hill; A V Alexandrov
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.